CL2014002522A1 - Agente inmunomodulador y usos para el mismo - Google Patents

Agente inmunomodulador y usos para el mismo

Info

Publication number
CL2014002522A1
CL2014002522A1 CL2014002522A CL2014002522A CL2014002522A1 CL 2014002522 A1 CL2014002522 A1 CL 2014002522A1 CL 2014002522 A CL2014002522 A CL 2014002522A CL 2014002522 A CL2014002522 A CL 2014002522A CL 2014002522 A1 CL2014002522 A1 CL 2014002522A1
Authority
CL
Chile
Prior art keywords
immunomodulatory agent
immunomodulatory
agent
Prior art date
Application number
CL2014002522A
Other languages
English (en)
Inventor
Ranjeny Thomas
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012901189A external-priority patent/AU2012901189A0/en
Application filed by Univ Queensland filed Critical Univ Queensland
Publication of CL2014002522A1 publication Critical patent/CL2014002522A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2014002522A 2012-03-23 2014-09-23 Agente inmunomodulador y usos para el mismo CL2014002522A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2012901189A AU2012901189A0 (en) 2012-03-23 Immunomodulatory agents and uses therefor

Publications (1)

Publication Number Publication Date
CL2014002522A1 true CL2014002522A1 (es) 2015-06-12

Family

ID=49221713

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002522A CL2014002522A1 (es) 2012-03-23 2014-09-23 Agente inmunomodulador y usos para el mismo

Country Status (17)

Country Link
US (1) US20150216955A1 (es)
EP (1) EP2827890B1 (es)
JP (2) JP2015512371A (es)
KR (1) KR20150010716A (es)
CN (2) CN110404062A (es)
AU (1) AU2013234815B2 (es)
BR (1) BR112014023572A2 (es)
CA (1) CA2868123A1 (es)
CL (1) CL2014002522A1 (es)
EA (1) EA201491748A1 (es)
IL (1) IL234756A0 (es)
MX (1) MX2014011488A (es)
MY (1) MY172706A (es)
NZ (1) NZ631340A (es)
PH (1) PH12014502063A1 (es)
SG (2) SG10201706208SA (es)
WO (1) WO2013138871A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238747B2 (en) 2010-12-13 2019-03-26 Cel-Sci, Corp Method for inducing an immune response against avian, swine, spanish, H1N1, H5N9 influenza viruses and formulations thereof
US10179174B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corp. Method for inducing an immune response and formulations thereof
US10179164B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
CN109771444A (zh) * 2019-04-03 2019-05-21 哈尔滨北极神生物工程有限公司 蜂胶氨糖人参皂甙复合胶囊及制备方法
US20220218806A1 (en) * 2019-05-11 2022-07-14 CRL-SCI Corporation Peptides and conjugates for treatment of arthritis
US20230086469A1 (en) * 2019-08-30 2023-03-23 Universidad De Chile Autoantigenic peptides (calvicifiv), presented by tolerogenic dentritic cells, useful for the personalized treatment of rheumatoid arthritis
CN115515614B (zh) * 2020-02-06 2024-07-23 尤尼根公司 用于改进关节健康和治疗关节炎的包含山姜属和其它植物提取物的组合物
JP6864131B1 (ja) 2020-03-04 2021-04-28 長瀬産業株式会社 Ｌ−エルゴチオネイン含有組成物
CN112675299B (zh) * 2021-01-06 2023-10-20 黑龙江省百洲生物工程有限公司 一种防控鹅星状病毒复合佐剂灭活疫苗的制备方法
CN115406986B (zh) * 2022-08-29 2024-12-24 上海复活石医药科技有限公司 一种包含蚕茧壳的中药组合物的质量控制方法及其应用
JPWO2024057793A1 (es) * 2022-09-13 2024-03-21
WO2024077071A2 (en) * 2022-10-05 2024-04-11 The Johns Hopkins University Nanoparticles for delivery of immunoregulatory materials to t cells
CN117092272B (zh) * 2023-07-04 2025-08-19 四川新绿色药业科技发展有限公司 萆薢配方颗粒薄层鉴别方法
CN117085118A (zh) * 2023-08-22 2023-11-21 北京大学人民医院 一种瓜氨酸化ii型胶原多肽疫苗及其应用
WO2025059634A1 (en) * 2023-09-15 2025-03-20 The Regents Of The University Of California Immunomodulatory nanoparticles for modulating arthritis flares
CN117986351B (zh) * 2023-12-29 2025-03-11 北京大学人民医院 一种ra自身抗原表位多肽及其制备的抗原特异性t细胞疫苗、制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
AU633007B2 (en) 1988-06-14 1993-01-21 Cell-Sci Corporation Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same
US6106840A (en) 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
FI87028C (fi) 1989-12-22 1992-11-10 Nokia Mobile Phones Ltd Metod foer att reglera effekt hos en spaenningsstyrd effektfoerstaerkare och koppling foer anvaendning i metoden
US5139749A (en) 1990-06-22 1992-08-18 Tas, Inc. Fluidized calcining process
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5234140A (en) 1992-07-28 1993-08-10 S. C. Johnson & Son, Inc. Re-useable aerosol container
US5817308A (en) 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
CA2251781A1 (en) 1996-03-20 1997-09-25 Charles Nicolette A method for identifying cytotoxic t-cell epitopes
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
CA2399028A1 (en) * 2000-03-23 2001-09-27 Akzo Nobel N.V. Use of mia in immunotherapy
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20030235610A1 (en) * 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
CA2421321A1 (en) * 2003-03-07 2004-09-07 London Health Sciences Centre Research Inc. Peptides associated with hla-dr mhc class ii molecule and involved in rheumatoid arthritis
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
WO2014176604A1 (en) * 2013-04-26 2014-10-30 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
JP2010505883A (ja) * 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
EP2254588B1 (en) 2008-03-14 2017-10-11 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
JPWO2009116246A1 (ja) 2008-03-17 2011-07-21 パナソニック株式会社 通信方法、通信システム、モバイルノード及びアクセスルータ
WO2010048388A1 (en) 2008-10-22 2010-04-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunoassays for citrullinated proteins
WO2010147898A2 (en) 2009-06-15 2010-12-23 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
WO2014141244A1 (en) * 2013-03-12 2014-09-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic peptides for the treatment of autoimmune diseases
CN105263476A (zh) * 2013-03-13 2016-01-20 库尔制药开发公司 用于治疗炎症的免疫修饰性颗粒

Also Published As

Publication number Publication date
PH12014502063A1 (en) 2014-12-10
MY172706A (en) 2019-12-11
EP2827890A1 (en) 2015-01-28
EA201491748A1 (ru) 2015-02-27
BR112014023572A2 (pt) 2017-09-12
SG11201405848UA (en) 2014-10-30
EP2827890A4 (en) 2015-11-25
JP2015512371A (ja) 2015-04-27
JP2019070034A (ja) 2019-05-09
KR20150010716A (ko) 2015-01-28
WO2013138871A1 (en) 2013-09-26
NZ631340A (en) 2016-11-25
CA2868123A1 (en) 2013-09-26
IL234756A0 (en) 2014-11-30
EP2827890B1 (en) 2019-08-28
US20150216955A1 (en) 2015-08-06
CN110404062A (zh) 2019-11-05
CN104519907A (zh) 2015-04-15
AU2013234815A1 (en) 2014-10-09
MX2014011488A (es) 2015-05-11
SG10201706208SA (en) 2017-08-30
AU2013234815B2 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
CL2014002522A1 (es) Agente inmunomodulador y usos para el mismo
IL269045A (en) Aptamers and uses thereof
NO2023026I1 (no) Dengue tetravalent vaccine
GB2535911B (en) Strigolactone formulations and uses thereof
BR112015003354A2 (pt) composições e métodos de microcápsula
CL2015000450A1 (es) Métodos y composiciones para el tratamiento de una afección genética
CL2016001241A1 (es) Nuevos compuestos pesticidas y usos
DK3360964T3 (da) Crispr-baseret genommodifikation og -regulering
EP2958994A4 (en) Vaccine composition
HUE048949T2 (hu) Algaextraktum immunmoduláló szerként történõ alkalmazásra
CY2200004T2 (el) Σκευασματα δαπτομυκινης και χρησεις αυτων
EP2961397A4 (en) TRANSDERMAL FORMULATIONS
BR112014026357A2 (pt) composição e sistema
DK2858604T3 (da) Ekspanderet anordning
BR112013006877A2 (pt) dispositivo de segurança e aparelho para inflá-lo
CL2014001401S1 (es) Soporte para globos
SMT202400191T1 (it) Composizione di inibitore di IL-1Beta e uso di essa
EP2860233A4 (en) PUNCTURE CLOSURE MEANS
PL3042669T3 (pl) Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy
BR112015007217A2 (pt) compostos e usos do composto
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
EP2905036A4 (en) IONISER
TWI562776B (en) Pharmaceutical composition and uses thereof
BR112015014386A2 (pt) dispositivo de distribuição de agente intramiocárdico e métodos relacionados
DE112013005825A5 (de) Reduktionsmittelzuführeinrichtung